Jinhai Medical Technology Limited
今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

VOLUNTARY ANNOUNCEMENT

The board (the "**Board**") of directors (the "**Directors**") of Jinhai Medical Technology Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Mr. Ma Chengdong（馬成棟先生）("**Mr. Ma**") is appointed as chief marketing officer of the Group with effect from 3 August 2026 for an initial term of one year, primarily responsible for the marketing strategy, market access, academic promotion and sales and channel operations of the Group's products, and overseeing the commercialisation of the Group's medical devices and equipment products (the "**Appointment**").

Set out below is the brief biography of Mr. Ma:

Mr. Ma Chengdong（馬成棟先生）

Mr. Ma, aged 55, graduated from Shanghai Medical University（上海醫科大學）(currently known as Shanghai Medical College of Fudan University（復旦大學上海醫學院）) specialising in clinical medicine. Mr. Ma completed a five-year residency training at the Shanghai Institute of Cardiovascular Diseases*（上海市心血管病研究所）, and has worked mainly on product, technology, marketing and sales at various international medical enterprises in aggregate for over 25 years, including (i) GE Medical (China) Co., Ltd.（通用電氣醫療（中國）有限公司）("**GE Medical China**"), a subsidiary of GE HealthCare Technologies Inc. with its shares listed on NASDAQ, where he served various positions including technical manager, product manager, regional sales director, Greater China marketing manager, acting Greater China general manager and general manager of clinical application and research team, and (ii) Medtronic (Shanghai) Management Co., Ltd.（美敦力（上海）管理公司）("**Medtronic China**"), a subsidiary of Medtronic plc with its shares listed on the New York Stock Exchange, where he served as general manager of strategic marketing department and general manager of commercial excellence operation of Chinese orthopaedic and neurosurgery practices.

REASONS AND BENEFITS OF THE APPOINTMENT

The Group expects that the future trends of the medical sector in Mainland China may develop in, amongst others, the following directions:

1. Intelligentization: AI is deeply integrated into image recognition, path planning and risk warning, enabling robots to achieve sub-millimetre precision in operation, significantly enhancing surgical standardization and safety;

2. Minimally invasiveness plus non-invasiveness: The widespread adoption of flexible instruments, nanomaterials, and intraoperative real-time imaging (low-dose CT/MRI/3D ultrasound) has the vision to bring trauma close to zero;

3. Acceleration of domestic substitution: Policy support (accelerated approval for Category III medical devices, green channel for innovative medical devices) and clinical demand pressures are driving the localization of high-end equipment; and

4. Integration of cutting-edge technologies: Brain-computer interface + robots + AI + neuromodulation is expected to combine to cover a full spectrum of applications including paralysis rehabilitation, Parkinson's disease, disorders of consciousness, and epilepsy, representing a core growth driver for the future.

In view of the Group's business focus on provision of minimally surgery solutions and medical products and related services in China (for instance, in the endoscopy related field), it is considered that the Group possesses certain advantages to enter into the neurosurgical endoscopy segment. Following the Appointment, the Group expects that its marketing and promotion capabilities in minimally invasiveness and non-invasiveness will be further improved and strengthened.

By Order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman of the Board and executive Director

Hong Kong, 3 August 2026

As at the date of this announcement, the Board comprises eight directors: the executive Directors are Mr. Chen Guobao, Mr. Li Bin, Mr. Wang Zhenfei and Mr. Li Yunping; the non-executive Director is Mr. Wang Huasheng; and the independent non-executive Directors are Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.

* *For identification purposes only*